PURPOSE: Brain stem gliomas account for 20% of childhood brain tumors. Presently, there is no effective treatment for these tumors, and the prognosis remains poor. One reason for this is that chemotherapeutic drugs cannot cross the blood-brain barrier. In this study, we used a rodent brainstem tumor model, monitored both qualitatively and quantitatively, to examine the effectiveness of vincristine (VCR) administered via convection-enhanced delivery (CED). METHODS: C6 rat glioblastoma cells, transduced with an oncoretroviral plasmid containing a luciferase coding sequence, were inoculated into Fischer 344 rat brainstems. Tumor growth was monitored by bioluminescence intensity (BLI), and tumor volume was calculated from serial histopathologic sections. Therapeutic efficacy of VCR delivered via CED was assessed. Intravenous (I.V.) and intraperitoneal (I.P.) drug administration were used as a comparison for CED efficacy. RESULTS: BLI monitoring revealed progressive tumor growth in inoculated rats. Symptoms caused by tumor burden were evident 16-18 days after inoculation. BLI correlated quantitatively with tumor volume (r(2) = 0.9413), established by histopathological analysis of tumor growth within the pons. VCR administered through CED was more effective than I.V. or I.P. administration in reducing tumor size and increasing survival times. TUNEL assay results suggest that VCR induced glioblastoma cell apoptosis. CONCLUSIONS: VCR administered by CED was effective in reducing tumors and prolonging survival time.
PURPOSE: Brain stem gliomas account for 20% of childhood brain tumors. Presently, there is no effective treatment for these tumors, and the prognosis remains poor. One reason for this is that chemotherapeutic drugs cannot cross the blood-brain barrier. In this study, we used a rodent brainstem tumor model, monitored both qualitatively and quantitatively, to examine the effectiveness of vincristine (VCR) administered via convection-enhanced delivery (CED). METHODS: C6 ratglioblastoma cells, transduced with an oncoretroviral plasmid containing a luciferase coding sequence, were inoculated into Fischer 344 rat brainstems. Tumor growth was monitored by bioluminescence intensity (BLI), and tumor volume was calculated from serial histopathologic sections. Therapeutic efficacy of VCR delivered via CED was assessed. Intravenous (I.V.) and intraperitoneal (I.P.) drug administration were used as a comparison for CED efficacy. RESULTS: BLI monitoring revealed progressive tumor growth in inoculated rats. Symptoms caused by tumor burden were evident 16-18 days after inoculation. BLI correlated quantitatively with tumor volume (r(2) = 0.9413), established by histopathological analysis of tumor growth within the pons. VCR administered through CED was more effective than I.V. or I.P. administration in reducing tumor size and increasing survival times. TUNEL assay results suggest that VCR induced glioblastoma cell apoptosis. CONCLUSIONS: VCR administered by CED was effective in reducing tumors and prolonging survival time.
Authors: Costas G Hadjipanayis; Revaz Machaidze; Milota Kaluzova; Liya Wang; Albert J Schuette; Hongwei Chen; Xinying Wu; Hui Mao Journal: Cancer Res Date: 2010-07-20 Impact factor: 12.701
Authors: Peter J Dickinson; Richard A LeCouteur; Robert J Higgins; John R Bringas; Richard F Larson; Yoji Yamashita; Michal T Krauze; John Forsayeth; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; John W Park; Mitchel S Berger; Krystof S Bankiewicz Journal: Neuro Oncol Date: 2010-05-20 Impact factor: 12.300
Authors: Weilian Yang; Tianyao Huo; Rolf F Barth; Nilendu Gupta; Michael Weldon; John C Grecula; Brian D Ross; Benjamin A Hoff; Ting-Chao Chou; Julia Rousseau; Hélène Elleaume Journal: J Neurooncol Date: 2010-06-25 Impact factor: 4.130
Authors: R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield Journal: Proc Natl Acad Sci U S A Date: 1994-03-15 Impact factor: 11.205
Authors: John H Sampson; Gary Archer; Christoph Pedain; Eva Wembacher-Schröder; Manfred Westphal; Sandeep Kunwar; Michael A Vogelbaum; April Coan; James E Herndon; Raghu Raghavan; Martin L Brady; David A Reardon; Allan H Friedman; Henry S Friedman; M Inmaculada Rodríguez-Ponce; Susan M Chang; Stephan Mittermeyer; David Croteau; Raj K Puri Journal: J Neurosurg Date: 2010-08 Impact factor: 5.115
Authors: D M Ashley; C D Riffkin; M M Lovric; T Mikeska; A Dobrovic; J A Maxwell; H S Friedman; K J Drummond; A H Kaye; H K Gan; T G Johns; C J Hawkins Journal: Br J Cancer Date: 2008-07-01 Impact factor: 7.640
Authors: Minjee Kim; Shiv K Gupta; Wenjuan Zhang; Surabhi Talele; Afroz S Mohammad; Janice Laramy; Ann C Mladek; Shuangling Zhang; Jann N Sarkaria; William F Elmquist Journal: Drug Metab Dispos Date: 2021-12-09 Impact factor: 3.922
Authors: Danielle M Burgenske; Surabhi Talele; Jenny L Pokorny; Ann C Mladek; Katrina K Bakken; Brett L Carlson; Mark A Schroeder; Lihong He; Zeng Hu; Gautham Gampa; Matthew L Kosel; Paul A Decker; Gaspar J Kitange; Anne Schmitt-Hoffmann; Felix Bachmann; Rachael A Vaubel; Jeanette E Eckel-Passow; Caterina Giannini; Paul McSheehy; Heidi A Lane; William F Elmquist; Jann N Sarkaria Journal: Neuro Oncol Date: 2022-03-12 Impact factor: 13.029
Authors: Trung N T Le; Heeseung Lim; Amanda M Hamilton; Katie M Parkins; Yuanxin Chen; Timothy J Scholl; John A Ronald Journal: Tomography Date: 2018-06